Kathleen S. Capps net worth and biography

Kathleen Capps Biography and Net Worth

Kathleen Capps is the Insider of Enanta Pharmaceuticals. They are 41 years old.

What is Kathleen S. Capps' net worth?: The estimated net worth of Kathleen S. Capps is at least $114.89 thousand as of December 5th, 2025. Capps owns 8,377 shares of Enanta Pharmaceuticals stock worth more than $114,891 as of April 28th. This net worth approximation does not reflect any other investments that Capps may own. Learn More about Kathleen S. Capps' net worth.
How do I contact Kathleen S. Capps?: The corporate mailing address for Capps and other Enanta Pharmaceuticals executives is 500 ARSENAL STREET, WATERTOWN MA, 02472. Enanta Pharmaceuticals can also be reached via phone at (617) 607-0800 and via email at [email protected]. Learn More on Kathleen S. Capps' contact information.
Has Kathleen S. Capps been buying or selling shares of Enanta Pharmaceuticals?: Kathleen S. Capps has not been actively trading shares of Enanta Pharmaceuticals in the last ninety days. Most recently, Kathleen S. Capps sold 323 shares of the business's stock in a transaction on Friday, December 5th. The shares were sold at an average price of $14.23, for a transaction totalling $4,596.29. Following the completion of the sale, the insider now directly owns 8,377 shares of the company's stock, valued at $119,204.71. Learn More on Kathleen S. Capps' trading history.
Who are Enanta Pharmaceuticals' active insiders?: Enanta Pharmaceuticals' insider roster includes Nathalie Adda (VP), Kathleen Capps (Insider), Tara Kieffer (Insider), Jay Luly (CEO), Brendan Luu (Insider), Paul Mellett, Jr. (Sr. VP of Fin. & Admin. and CFO ), Yat Or (Insider), and Scott Rottinghaus (Insider). Learn More on Enanta Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Enanta Pharmaceuticals?: During the last year, insiders at the biotechnology company sold shares 7 times. They sold a total of 11,961 shares worth more than $170,149.14. The most recent insider tranaction occured on December, 5th when insider Kathleen S Capps sold 323 shares worth more than $4,596.29. Insiders at Enanta Pharmaceuticals own 11.5% of the company. Learn More about insider trades at Enanta Pharmaceuticals.
Information on this page was last updated on 12/5/2025.

Kathleen S. Capps Insider Trading History at Enanta Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
12/5/2025	Sell	323	$14.23	$4,596.29	8,377
12/2/2025	Sell	207	$13.96	$2,889.72	8,700

Kathleen S. Capps Buying and Selling Activity at Enanta Pharmaceuticals

Enanta Pharmaceuticals Company Overview

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts.

Today's Range

Now: $13.71

$13.26

$13.78

50 Day Range

MA: $13.55

$12.08

$15.41

2 Week Range

Now: $13.71

$4.96

$17.15

Volume

102,662 shs

Average Volume

182,022 shs

Market Capitalization

$397.86 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.99